Division of Viral Disease and Epidemiology, National Institute of Animal Health, National Agricultural Research Organization, Tsukuba, Ibaraki 3050856, Japan.
Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 5650871, Japan.
Viruses. 2018 Aug 30;10(9):467. doi: 10.3390/v10090467.
Base on the sequence of genes, which encode spike proteins, we previously identified three different types (North American, S INDEL, and S large-DEL types) of porcine epidemic diarrhea virus (PEDV) that have re-emerged in Japan since 2013. Based on experimental infections with the North American and S large-DEL types, we also hypothesized that PEDV virulence may be linked to the S1 subunit of the S protein. To test this hypothesis, we have now assayed in gnotobiotic piglets various recombinant PEDVs generated by reverse genetics. Piglets inoculated with CV777 maintained in National Institute of Animal Health, along with piglets infected with a recombinant form of the same virus, developed subclinical to mild diarrhea. In contrast, severe watery diarrhea, dehydration, weight loss, astasia, and high mortality were observed in piglets inoculated with recombinant strains in which the gene was partially or fully replaced with corresponding sequences from the highly virulent Japanese PEDV isolate OKN-1/JPN/2013. Indeed, symptoms resembled those in piglets inoculated with the OKN-1/JPN/2013, and were especially pronounced in younger piglets. Collectively, the data demonstrate that the S1 subunit of the S protein is an important determinant of PEDV virulence, and advance development of new vaccine candidate.
基于编码刺突蛋白的基因序列,我们之前鉴定出自 2013 年以来在日本重新出现的三种不同类型的猪流行性腹泻病毒(PEDV):北美型、S INDEL 型和 S 大片段缺失型。基于对北美型和 S 大片段缺失型的实验性感染,我们还假设 PEDV 的毒力可能与 S 蛋白的 S1 亚单位有关。为了验证这一假设,我们现在使用反向遗传学生成的各种重组 PEDV 对无菌仔猪进行了检测。接种保存在国立动物卫生研究所的 CV777 的仔猪,以及接种相同病毒重组形式的仔猪,出现亚临床至轻度腹泻。相比之下,在接种用来自高毒力日本 PEDV 分离株 OKN-1/JPN/2013 的相应序列部分或完全替换了基因的重组株的仔猪中,观察到严重的水样腹泻、脱水、体重减轻、站立不稳和高死亡率。事实上,症状类似于接种 OKN-1/JPN/2013 的仔猪,而且在年幼仔猪中更为明显。总的来说,这些数据表明 S 蛋白的 S1 亚单位是 PEDV 毒力的重要决定因素,并推进了新疫苗候选物的开发。